 Kalyan Latchamsetty
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrectomy | 3 | 2018 | 44 | 1.620 |
Why?
| | Prostatic Neoplasms | 8 | 2018 | 122 | 1.460 |
Why?
| | Kidney Neoplasms | 2 | 2018 | 78 | 0.830 |
Why?
| | Carcinoma, Renal Cell | 1 | 2018 | 46 | 0.700 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2017 | 6 | 0.670 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 91 | 0.660 |
Why?
| | Renal Veins | 1 | 2017 | 3 | 0.660 |
Why?
| | Image-Guided Biopsy | 1 | 2017 | 31 | 0.660 |
Why?
| | Surgical Stapling | 1 | 2017 | 9 | 0.650 |
Why?
| | Renal Artery | 1 | 2017 | 10 | 0.650 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 37 | 0.650 |
Why?
| | Laparoscopy | 2 | 2017 | 190 | 0.640 |
Why?
| | Ultrasonography | 1 | 2017 | 210 | 0.600 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 106 | 0.600 |
Why?
| | Prostate | 5 | 2018 | 36 | 0.580 |
Why?
| | Postoperative Complications | 3 | 2018 | 1083 | 0.570 |
Why?
| | Lung Neoplasms | 1 | 2018 | 756 | 0.460 |
Why?
| | Neoplasm Staging | 2 | 2018 | 481 | 0.440 |
Why?
| | Prostate-Specific Antigen | 3 | 2006 | 17 | 0.400 |
Why?
| | Rectum | 3 | 2018 | 72 | 0.360 |
Why?
| | Middle Aged | 12 | 2018 | 11209 | 0.340 |
Why?
| | Drug Resistance, Bacterial | 2 | 2018 | 55 | 0.340 |
Why?
| | Adenocarcinoma | 2 | 2007 | 237 | 0.330 |
Why?
| | Aorta, Abdominal | 1 | 2007 | 11 | 0.320 |
Why?
| | Vena Cava, Inferior | 1 | 2007 | 14 | 0.320 |
Why?
| | Aged | 11 | 2018 | 10295 | 0.310 |
Why?
| | Retrospective Studies | 5 | 2018 | 3591 | 0.300 |
Why?
| | Pneumothorax | 1 | 2005 | 12 | 0.280 |
Why?
| | Kidney Transplantation | 1 | 2007 | 141 | 0.280 |
Why?
| | Kidney | 1 | 2007 | 210 | 0.280 |
Why?
| | Incidence | 2 | 2018 | 829 | 0.280 |
Why?
| | Kidney Failure, Chronic | 1 | 2007 | 176 | 0.270 |
Why?
| | Unnecessary Procedures | 1 | 2005 | 30 | 0.270 |
Why?
| | Clinical Competence | 1 | 2007 | 274 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 2 | 2007 | 1273 | 0.250 |
Why?
| | Aged, 80 and over | 5 | 2018 | 5234 | 0.240 |
Why?
| | Genital Neoplasms, Male | 1 | 2002 | 3 | 0.240 |
Why?
| | Seminal Vesicles | 1 | 2002 | 4 | 0.240 |
Why?
| | Neurilemmoma | 1 | 2002 | 15 | 0.240 |
Why?
| | Male | 11 | 2018 | 17583 | 0.210 |
Why?
| | Humans | 13 | 2018 | 31481 | 0.210 |
Why?
| | Adult | 6 | 2018 | 9779 | 0.190 |
Why?
| | Fluoroquinolones | 1 | 2018 | 25 | 0.180 |
Why?
| | African Americans | 1 | 2006 | 818 | 0.180 |
Why?
| | False Positive Reactions | 1 | 2018 | 40 | 0.180 |
Why?
| | Follow-Up Studies | 2 | 2018 | 2028 | 0.170 |
Why?
| | Treatment Outcome | 4 | 2017 | 3910 | 0.170 |
Why?
| | Lung | 1 | 2018 | 171 | 0.170 |
Why?
| | Urology | 1 | 2017 | 16 | 0.170 |
Why?
| | Models, Educational | 1 | 2017 | 41 | 0.160 |
Why?
| | Microbial Sensitivity Tests | 1 | 2017 | 117 | 0.160 |
Why?
| | Ligation | 1 | 2017 | 37 | 0.160 |
Why?
| | Arteriovenous Fistula | 1 | 2017 | 13 | 0.160 |
Why?
| | Postoperative Period | 1 | 2018 | 295 | 0.160 |
Why?
| | Operative Time | 1 | 2017 | 97 | 0.160 |
Why?
| | Predictive Value of Tests | 3 | 2007 | 637 | 0.150 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 389 | 0.140 |
Why?
| | Anti-Bacterial Agents | 1 | 2018 | 412 | 0.140 |
Why?
| | Internship and Residency | 1 | 2017 | 201 | 0.130 |
Why?
| | Prostatectomy | 2 | 2005 | 23 | 0.130 |
Why?
| | Prospective Studies | 4 | 2007 | 1934 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 891 | 0.120 |
Why?
| | Biopsy | 2 | 2018 | 283 | 0.110 |
Why?
| | Biopsy, Needle | 3 | 2006 | 117 | 0.110 |
Why?
| | Young Adult | 1 | 2017 | 2277 | 0.100 |
Why?
| | Female | 4 | 2018 | 18253 | 0.100 |
Why?
| | Comorbidity | 2 | 2018 | 562 | 0.090 |
Why?
| | Uterine Prolapse | 1 | 2007 | 5 | 0.080 |
Why?
| | Physical Examination | 2 | 2005 | 116 | 0.080 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2007 | 13 | 0.080 |
Why?
| | Surgical Mesh | 1 | 2007 | 30 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2007 | 29 | 0.080 |
Why?
| | Digital Rectal Examination | 1 | 2006 | 4 | 0.080 |
Why?
| | Anastomosis, Surgical | 1 | 2007 | 56 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2007 | 48 | 0.080 |
Why?
| | Graft Survival | 1 | 2007 | 111 | 0.080 |
Why?
| | Urination Disorders | 1 | 2005 | 6 | 0.070 |
Why?
| | Pleura | 1 | 2005 | 7 | 0.070 |
Why?
| | Auscultation | 1 | 2005 | 7 | 0.070 |
Why?
| | Respiratory Sounds | 1 | 2005 | 11 | 0.070 |
Why?
| | Case Management | 1 | 2005 | 15 | 0.070 |
Why?
| | Radiography, Thoracic | 1 | 2005 | 39 | 0.070 |
Why?
| | Catheterization, Central Venous | 1 | 2005 | 44 | 0.070 |
Why?
| | Intraoperative Complications | 1 | 2005 | 76 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2007 | 886 | 0.060 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2007 | 300 | 0.060 |
Why?
| | Risk Assessment | 1 | 2007 | 806 | 0.060 |
Why?
| | Receptors, Glutamate | 1 | 2003 | 4 | 0.060 |
Why?
| | Somatosensory Cortex | 1 | 2003 | 5 | 0.060 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2003 | 22 | 0.060 |
Why?
| | Neural Pathways | 1 | 2003 | 83 | 0.060 |
Why?
| | Length of Stay | 1 | 2005 | 377 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2007 | 1240 | 0.060 |
Why?
| | Cohort Studies | 1 | 2007 | 2014 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2018 | 63 | 0.040 |
Why?
| | Bacterial Infections | 1 | 2018 | 71 | 0.040 |
Why?
| | Self Report | 1 | 2017 | 225 | 0.040 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 181 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2006 | 390 | 0.030 |
Why?
| | Time Factors | 1 | 2017 | 1902 | 0.030 |
Why?
| | Risk Factors | 1 | 2018 | 2664 | 0.030 |
Why?
| | Databases, Factual | 1 | 2007 | 391 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2005 | 73 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 580 | 0.020 |
Why?
| | 2-Amino-5-phosphonovalerate | 1 | 2003 | 3 | 0.020 |
Why?
| | Rats, Long-Evans | 1 | 2003 | 14 | 0.020 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2003 | 35 | 0.010 |
Why?
| | Functional Laterality | 1 | 2003 | 96 | 0.010 |
Why?
| | Age Factors | 1 | 2005 | 943 | 0.010 |
Why?
| | Prognosis | 1 | 2005 | 1028 | 0.010 |
Why?
| | Brain Mapping | 1 | 2003 | 199 | 0.010 |
Why?
| | Rats | 1 | 2003 | 966 | 0.010 |
Why?
| | Animals | 1 | 2003 | 5312 | 0.010 |
Why?
|
|
Latchamsetty's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|